Tumor infiltrating lymphocytes in HER2-positive breast cancer patients treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: A meta-analysis of published randomized clinical trials

被引：0
|
作者：
Solinas, C. [1 ]
Ceppi, M. [2 ]
Lambertini, M. [3 ]
Scartozzi, M. [4 ]
Garaud, S. [5 ]
Fumagalli, D. [6 ]
De Azambuja, E. [7 ]
Salgado, R. [8 ]
Willard-Gallo, K. [5 ]
Ignatiadis, M. [9 ]
机构：
[1] Univ Libre Bruxelles, Inst Jules Bordet, Mol Immunol Unit, Brussels, Belgium
[2] IRCCS AOU San Martino IST, Unit Clin Epidemiol, Genoa, Italy
[3] Univ Libre Bruxelles, Inst Jules Bordet, Breast Canc Translat Res Lab, Brussels, Belgium
[4] Univ Cagliari, Med Oncol, Cagliari, Italy
[5] Inst Jules Bordet, Mol Immunol Unit, Brussels, Belgium
[6] Breast Int Grp, Brussels, Belgium
[7] Univ Libre Bruxelles, Inst Jules Bordet, BrREAST Data Ctr, Brussels, Belgium
[8] GZA Ziekenhuizen, Dept Pathol, Sint Augustinus Campus, Antwerp, Belgium
[9] Univ Libre Bruxelles, Inst Jules Bordet, Acad Trials Promoting Unit, Brussels, Belgium
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
27P
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: A meta-analysis of randomized controlled trials
    Solinas, C.
    Ceppi, M.
    Lambertini, M.
    Scartozzi, M.
    Buisseret, L.
    Garaud, S.
    Fumagalli, D.
    de Azambuja, E.
    Salgado, R.
    Sotiriou, C.
    Willard-Gallo, K.
    Ignatiadis, M.
    [J]. CANCER TREATMENT REVIEWS, 2017, 57 : 8 - 15
  • [2] The efficiency and safety of trastuzumab and lapatinib added to neoadjuvant chemotherapy in Her2-positive breast cancer patients: a randomized meta-analysis
    Chen, Zhe-Ling
    Shen, Yan-Wei
    Li, Shu-Ting
    Li, Chun-Li
    Zhang, Ling-Xiao
    Yang, Jiao
    Lv, Meng
    Lin, Ya-Yun
    Wang, Xin
    Yang, Jin
    [J]. ONCOTARGETS AND THERAPY, 2016, 9 : 3233 - 3247
  • [3] Survival after neoadjuvant therapy with trastuzumab-lapatinib and chemotherapy in patients with HER2-positive early breast cancer: a meta-analysis of randomized trials
    Guarneri, V
    Griguolo, G.
    Miglietta, F.
    Conte, P. F.
    Dieci, M., V
    Girardi, F.
    [J]. ESMO OPEN, 2022, 7 (02)
  • [4] ADJUVANT TRASTUZUMAB THERAPY IN HER2-POSITIVE BREAST CANCER PATIENTS: A META-ANALYSIS OF PUBLISHED RANDOMIZED TRIALS
    Xia, Y.
    Bian, B.
    Costea, E.
    Kelton, C. M.
    Guo, J. J.
    [J]. VALUE IN HEALTH, 2013, 16 (03) : A128 - A128
  • [5] Adjuvant Trastuzumab Therapy in HER2-Positive Breast Cancer Patients: A Meta-Analysis of Published Randomized Trials
    Xia, Ying
    Bian, Boyang
    Costea, Elizabeth
    Guo, Jeff
    Kelton, Christina
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2013, 22 : 131 - 132
  • [6] Tumor-infiltrating lymphocytes (TILs) in HER2-positive (HER2+) early breast cancer treated with neoadjuvant lapatinib and trastuzumab without chemotherapy in the PAMELA Trial
    Nuciforo, P.
    Prat, A.
    Llombart, A.
    Fasani, R.
    Pare, L.
    Pascual, T.
    Oliveira, M.
    Martinez Janez, N.
    Bermejo De las Heras, B.
    Vidal, M.
    Pernas Simon, S.
    Lopez, R.
    Munoz, M.
    Garau, I.
    Manso, L.
    Alarcon Company, J.
    Martinez de Duenas, E.
    Villagrasa Gonzalez, P.
    Cortes Castan, J.
    Holgado, E.
    [J]. ANNALS OF ONCOLOGY, 2017, 28
  • [7] Analysis of tumor infiltrating lymphocytes in HER2-positive primary breast cancer treated with neoadjuvant lapatinib and trastuzumab: The NeoLath study (JBCRG-16).
    Kawaguchi, Kosuke
    Suzuki, Eiji
    Kataoka, Tatsuki R.
    Hirata, Masahiro
    Ohno, Shinji
    Bando, Hiroko
    Ishiguro, Hiroshi
    Inoue, Kenichi
    Yamamoto, Naohito
    Kuroi, Katsumasa
    Morita, Satoshi
    Masuda, Norikazu
    Toi, Masakazu
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [8] Survival after neoadjuvant therapy with trastuzumab-lapatinib and chemotherapy in patients with HER2-positive early breast cancer: A meta-analysis of randomised trials
    Guarneri, V.
    Griguolo, G.
    Miglietta, F.
    Conte, P. F.
    Dieci, M. V.
    Girardi, F.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S407 - S407
  • [9] Dual Block with Lapatinib and Trastuzumab Versus Single-Agent Trastuzumab Combined with Chemotherapy as Neoadjuvant Treatment of HER2-Positive Breast Cancer: A Meta-analysis of Randomized Trials
    Clavarezza, Matteo
    Puntoni, Matteo
    Gennari, Alessandra
    Paleari, Laura
    Provinciali, Nicoletta
    D'Amico, Mauro
    DeCensi, Andrea
    [J]. CLINICAL CANCER RESEARCH, 2016, 22 (18) : 4594 - 4603
  • [10] Dual block versus single agent trastuzumab plus chemotherapy as neoadjuvant treatment of HER2-positive breast cancer: a meta-analysis of randomized trials
    Clavarezza, M.
    Puntoni, M.
    Gennari, A.
    Paleari, L.
    Provinciali, N.
    D'Amico, M.
    Decensi, A.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
12345